Single Inhaler Triple Therapy Effective for COPD Single Inhaler Triple Therapy Effective for COPD
A single inhaler triple therapy provides clinical benefits superior to those of the muscarinic antagonist tiotropium alone in patients with symptomatic chronic obstructive pulmonary disease (COPD), according to the TRINITY trial.Reuters Health Information
ConclusionsCommunity pharmacist–delivered inhaler training informed by a digital technology improved adherence and health status.
ConclusionsPatients may adapt their ICS use to their current needs without this impacting later RDAC.
Publication date: Available online 3 October 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Vicente Plaza, Jordi Giner, Elena Curto, M. Belén Alonso-Ortiz, Miren Itxaso Orue, José María Vega, Borja G. Cosío, the group of investigators of the RE-TAI study (see annex file)AbstractBackgroundSatisfaction with the inhaler is an important determinant of treatment adherence in patients with asthma and COPD. However, few studies have compared these two groups to identify the factors associated with satisfaction with the inhaler.ObjectiveTo assess and compare satisfacti...
ConclusionCommunity pharmacist-delivered inhaler training informed by a digital technology improved adherence and health status.
This study assessed omalizumab outcomes in real-world patients with allergic asthma stratified by pretreatment biomarker levels. METHODS: Patients with allergic asthma aged ≥12 years initiated on omalizumab with ≥12 months of data after index were identified in the Allergy Partners electronic medical records (2007-2018). Patients with ≥1 diagnosis of chronic obstructive pulmonary disease in combination with ≥10 pack-years of smoking, cystic fibrosis, Alpha-1 antitrypsin deficiency, bronchiectasis, interstitial lung disease, and sarcoidosis in the 12 months before or after index were excluded. Patients were...
Publication date: Available online 18 September 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Marcia Vervloet, Liset van Dijk, Peter Spreeuwenberg, David Price, Alison Chisholm, Eric Van Ganse, Hilary Pinnock, Cynthia S. Rand, Michelle N. Eakin, Tjard Schermer, Patrick C. Souverein, Alexandra L. Dima, Respiratory Effectiveness Group’s Adherence Working GroupAbstractBackgroundLow inhaled corticosteroids (ICS) adherence is associated with increased asthma burden. This relationship is likely bidirectional, and may vary across adherence stages (initiation, implementation, persistence)....
ConclusionsThe current ACO definitions identify distinct populations that share only a small number of common features and present with different disease phenotypes. ACO prevalence is highly variable, depending on the definition applied.
Asthma and chronic obstructive pulmonary disease (COPD) are markedly different airway diseases, but sometimes they overlap, with some asthmatic patients showing some features of COPD (fixed airway obstruction, mixed neutrophilic/eosinophilic airway inflammation, and relatively poor response to corticosteroids) and some patients with COPD having features of asthma (atopy, history of asthma, greater airway reversibility, increased blood and sputum eosinophil counts, and a clinical response to corticosteroids).
Criner et al (N Engl J Med 2019; https://doi.org/10.1056/NEJMoa1905248) recently examined the effect of eosinophil depletion mediated by the IL-5 receptor α–blocking mAb benralizumab on the exacerbation rate of patients with chronic obstructive pulmonary disease (COPD) and high blood eosinophil counts in 2 large, complementary, phase 3, randomized controlled trials (GALATHEA and TERRANOVA). In both trials no statistically significant differences in annualized exacerbation rates were observed at any dose of benralizumab compared with placebo, despite substantial depletion of blood and sputum eosinophils.
PMID: 31376487 [PubMed - as supplied by publisher]